Results 11 to 20 of about 119,167 (297)

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets [PDF]

Diabetologia, 1985
Glucagon-like peptide-1 and glucagon-like peptide-2 are encoded by the m-RNA of pancreatic preproglucagon. They show high conservation in different species and substantial sequence homology to glucagon. Because no definite biological activity of these peptides has been reported, we investigated the effect of synthetic C-terminally amidated glucagon ...
W E, Schmidt, E G, Siegel, W, Creutzfeldt   +2 more
openaire   +4 more sources

Adult human biliary tree stem cells differentiate to β-pancreatic islet cells by treatment with a recombinant human Pdx1 peptide [PDF]

, 2015
Generation of β-pancreatic cells represents a major goal in research. The aim of this study was to explore a protein-based strategy to induce differentiation of human biliary tree stem cells (hBTSCs) towards β-pancreatic cells.
Alvaro, Domenico, Berloco, Pasquale Bartolomeo, Cardinale, Vincenzo, Carpino, Guido, Casa, Domenico, DE CANIO, Michele, Federici, Giorgio, Gaudio, Eugenio, Maroder, Marella, Nevi, Lorenzo, Panetta, Rocco, Puca, Rosa, Reid, Lola M., Renzi, Anastasia, Scafetta, Gaia, Sicilia, Francesca   +15 more
core   +19 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [PDF]

Current Opinion in Lipidology, 2016
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes effects.
Thomas A. Lutz, Elena Osto
openaire   +2 more sources

GLP1R rs3765467 Polymorphism Is Associated with the Risk of Early Onset Type 2 Diabetes

International Journal of Endocrinology, 2023
Objective. To investigate the relationship between glucagon-like peptide-1 receptor gene polymorphisms and susceptibility to early onset type 2 diabetes. Methods.
Yunyun Fang, Jingjing Zhang, Linlin Ji, Chaoyu Zhu, Yuanyuan Xiao, Qingge Gao, Wenjing Song, Li Wei   +7 more
doaj   +1 more source

Harnessing the Incretin System with Multi-Agonists

European Medical Journal Innovations, 2022
The scientific community has made great strides in responding to the huge public health problems of obesity and diabetes with the discovery of the incretin system and the development of glucagon-like peptide 1 analogues.
Martin B Whyte, Adrian Heald, Benjamin CT Field   +2 more
doaj   +1 more source

Liraglutide and renal outcomes in type 2 diabetes [PDF]

, 2017
In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks ...
Brown-Frandsen, Kirstine, Buse, John B., Mann, Johannes F. E, Maranghi, M., Marso, Steven P, Poulter, Neil R, Rasmussen, Søren, Tornøe, Karen, Zinman, Bernard, Ørsted, David D   +9 more
core   +2 more sources

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1 [PDF]

, 2011
The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2.
A. Linneberg, A. Sandbaek, B. Hartmann, D. R. Witte, H. Kissow, I. A. Hainerová, J. J. Holst, J. Lebl, J. Wang, L. Ma, M. Rosenkilde, N. Grarup, null null, O. D. Madsen, O. Pedersen, S. Madsbad, S. S. Torekov, T. Hansen, T. Jørgensen, T. Lauritzen, U. Kielgast   +20 more
core   +1 more source

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Clar, C., Royle, Pamela, Sharma, Pawana, Shyangdan, D. (Deepson), Waugh, Norman   +4 more
core   +5 more sources

Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes [PDF]

Diabetes, Obesity and Metabolism, 2022
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have become agents of choice for people with type 2 diabetes (T2D) with established cardiovascular disease or in high‐risk individuals. With currently available GLP‐1 RAs, 51%‐79% of subjects achieve an HbA1c target of less than 7.0% and 4%‐27% lose 10% of body weight ...
Christophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal   +3 more
openaire   +3 more sources